Anhui promotes the landing of "17 + 13 + X" anticancer drugs for the benefit of the people

[China Pharmaceutical network industry trends] recently, Anhui Provincial Medical centralized procurement platform forwarded a notice on the implementation of "17 + 13 + X" anticancer drugs for the benefit of the people The so-called "17 + 13 + X" refers to 17 kinds of anticancer drugs included in the medical insurance catalog, 13 kinds of successful negotiations, and X kinds of anticancer drugs to be purchased in volume in the future According to the notice, according to the requirement of "including more life-saving and emergency drugs into the medical insurance", the state health insurance bureau included 17 kinds of anti-cancer drugs into the basic medical insurance, work injury insurance and maternity insurance catalogue through negotiation and significantly reduced the price On the basis of the negotiation organized by the state health insurance bureau, the provincial-level purchasing organization with large amount of anticancer drugs was selected from the existing medical insurance catalogue, and 13 kinds of negotiation were successful, with substantial price reduction In the future, we will timely select x kinds of anticancer drugs to purchase in tissue volume, and constantly expand the types of anticancer drugs benefiting insured patients In order to ensure that the anti-cancer drugs can be purchased, used and reimbursed at a reduced price, and benefit the vast number of patients as soon as possible, we hereby set up the "17 + 13 + X" anti-cancer drugs benefiting the people landing mechanism notice According to the notice, the cost of "17 + 13 + X" anticancer drugs by the health and medical security departments is not included in the assessment scope of "drug proportion" and "three fees" (materials, drugs, inspection and test costs) for each time   It is worth mentioning that as early as November 29, 2018, the office of the National Health Insurance Bureau, the general office of the Ministry of human resources and social security and the general office of the national health and Health Commission jointly issued the notice on doing a good job in the implementation of 17 national health insurance negotiation anticancer drugs, which made it clear that the local health insurance, human resources social security and health departments should put forward specific requirements for the implementation of the negotiation drugs according to their responsibilities Strong guidance and scheduling shall not affect the supply and rational drug demand of negotiated drugs on the grounds of total cost control, "drug proportion" and basic drug use catalogue of medical institutions Anhui Province also stressed that the cost of "17 + 13 + X" anticancer drugs is not included in the assessment scope of "drug proportion" and "three fees per time", so it can be seen that the rational use of anticancer drugs will be further guaranteed In terms of cost clearing, the notice requires that when the medical security department conducts the cost clearing of medical institutions at the end of 2018 and 2019, "17 + 13" anticancer drug costs are not included in the total control scope, and the reasonable use costs are separately accounted for and guaranteed When formulating the total amount control index in 2020, we should take into account the reasonable use of "17 + 13" anticancer drugs and other factors, and adjust the total amount control quota of the fund in a timely manner At the same time, the cost of "X" anticancer drugs purchased with volume in the future will not be included in the control scope of the total amount of medical insurance in that year, and the cost of reasonable use will be separately accounted and guaranteed When formulating the total amount control index of the next year, the reasonable use of "17 + 13 + X" anticancer drugs and other factors shall be considered as a whole, and the total amount control quota of the fund shall be adjusted in time In addition, all localities should adjust the medication catalogue and disease settlement quota of chronic disease medical insurance, and include "17 + 13 + X" negotiation anticancer drugs into the overall payment scope of outpatient service In terms of supervision, Anhui provincial drug procurement center is required to classify, mark and prompt "17 + 13 + X" anticancer drugs on the provincial medicine centralized procurement platform, so as to ensure that hospitals give priority to procurement and use on the premise of ensuring treatment effect The dosage of "17 + 13 + X" anticancer drugs will be monitored dynamically It can be seen that Anhui Province has further implemented the work of reducing the price of anticancer drugs, and at the same time, it is required to collect money on time to ensure that the burden of enterprises is reduced The notice requires urging medical institutions to use "17 + 13 + X" anticancer drugs as soon as possible, which also means that patients in Anhui Province are expected to use cheaper and affordable "17 + 13 + X" anticancer drugs as soon as possible to reduce the drug burden.